Search - tctmd.com

Displaying 21 - 40 of 66

Sort: Relevancy | Date

News Conference News ESC 2017

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

Michael O'Riordan

August 30, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

Michael O'Riordan

May 30, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Daily News

Statins Seem to Reduce Alzheimer’s Disease Risk, But Race/Ethnicity and Statin Type Matter

Todd Neale

December 14, 2016

News Daily News

Al parecer las estatinas reducen el riesgo de la Enfermedad de Alzheimer, pero se deben tener en cuenta el tipo de estatina y la raza/etnicidad.

Todd Neale

December 14, 2016

News Daily News

Avoid Simvastatin, Lovastatin in Dabigatran-Treated Patients, Analysis Suggests

Todd Neale

November 24, 2016

News Daily News

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

Michael O'Riordan

November 10, 2016

News Daily News

El Tratamiento con Estatinas de Alta Intensidad Ofrece una Mayor Supervivencia sobre las Estatinas de Intensidad Moderada en Pacientes con Enfermedad Cardiovascular

Michael O'Riordan

November 10, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Daily News

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Michael O'Riordan

July 12, 2016

News Daily News

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

Michael O'Riordan

June 13, 2016

News Daily News

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Michael O'Riordan

June 13, 2016

News Conference News EAS 2016

Statin-Associated Muscle Symptoms: Real or ‘Artificial,’ Physicians Should Take Time to Manage Patients

Yael L. Maxwell

June 01, 2016

News Daily News

Statins Tied to Lower Mortality, Amputation Risks in PAD

Michael O'Riordan

May 09, 2016

News Features

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

Michael O'Riordan

May 03, 2016

News Daily News

No More Niacin, Fibrate Combinations With Statins: FDA

Michael O'Riordan

April 19, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

Advertisement

Women at High Cardiovascular Risk Unlikely to Get to Low LDL Targets

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Post-MI High-Intensity Statin Use Has Doubled in Recent Years

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Statins Seem to Reduce Alzheimer’s Disease Risk, But Race/Ethnicity and Statin Type Matter

Al parecer las estatinas reducen el riesgo de la Enfermedad de Alzheimer, pero se deben tener en cuenta el tipo de estatina y la raza/etnicidad.

Avoid Simvastatin, Lovastatin in Dabigatran-Treated Patients, Analysis Suggests

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

El Tratamiento con Estatinas de Alta Intensidad Ofrece una Mayor Supervivencia sobre las Estatinas de Intensidad Moderada en Pacientes con Enfermedad Cardiovascular

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Time for Niacin to Be ‘Relegated to Medical History’ as HPS2-THRIVE Analysis Confirms Drug’s Failings

Adverse Events Linked with Statins Get a Second Look From Cholesterol Treatment Trialists’ Collaboration

La Colaboración de Ensayistas para el Tratamiento del Colesterol Vuelve a Analizar los Episodios Adversos secundarios a las Estatinas

Statin-Associated Muscle Symptoms: Real or ‘Artificial,’ Physicians Should Take Time to Manage Patients

Statins Tied to Lower Mortality, Amputation Risks in PAD

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

No More Niacin, Fibrate Combinations With Statins: FDA

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content